Insider Selling: Cerus (NASDAQ:CERS) Director Sells $53,180.40 in Stock

Cerus Corporation (NASDAQ:CERS) Director Eric Bjerkholt sold 20,454 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $2.60, for a total value of $53,180.40. Following the completion of the sale, the director directly owned 261,679 shares in the company, valued at $680,365.40. This represents a 7.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Cerus Stock Down 1.2%

CERS opened at $2.56 on Friday. Cerus Corporation has a one year low of $1.15 and a one year high of $3.15. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.06 and a current ratio of 1.63. The stock’s fifty day moving average is $2.36 and its 200-day moving average is $2.20. The company has a market capitalization of $512.95 million, a PE ratio of -51.20 and a beta of 1.77.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%.The company had revenue of $59.89 million for the quarter, compared to the consensus estimate of $55.68 million. On average, equities analysts predict that Cerus Corporation will post -0.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Cerus

Institutional investors and hedge funds have recently modified their holdings of the stock. Cibc World Markets Corp purchased a new position in shares of Cerus during the fourth quarter valued at $25,000. MML Investors Services LLC purchased a new position in shares of Cerus during the fourth quarter valued at $37,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Cerus by 68.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 7,603 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Cerus during the first quarter valued at $35,000. Finally, Bingham Private Wealth LLC purchased a new position in shares of Cerus during the fourth quarter valued at $40,000. 78.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on the company. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Friday, May 1st. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a research report on Wednesday, March 25th. Finally, Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Cerus presently has a consensus rating of “Hold” and a consensus price target of $4.00.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.